Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin
Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, Friedewald W
Published in Journal of the American College of Cardiology
Methodology
Long-term mortality follow-up of the randomised Coronary Drug Project comparing niacin with placebo in men with prior myocardial infarction, in the pre-statin era.
Key Findings
Niacin was associated with an 11% lower all-cause mortality at 15 years, roughly nine years after treatment ended.
Conclusions
Niacin monotherapy reduced long-term mortality in the pre-statin era, a context that no longer reflects modern care.
Limitations
Historic trial without background statin therapy; post-hoc long-term follow-up.
Supplements Studied
Niacin was associated with an 11% lower all-cause mortality at 15 years in the pre-statin Coronary Drug Project.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.